A high percentage of LAG3+ T cells in relapsed/refractory diffuse large B cell lymphoma (R/R-DLBCL) patients is a biomarker of T cell exhaustion and correlates with lower ORR and higher recurrence rate after CD19 CAR-T cell therapy [67]. Here, CD19 is linked to diffuse large B-cell lymphoma.